Finding your next opportunity shouldn’t require piecing together multiple databases, alerts and research tools.
Fundz combines its own funding and M&A intelligence with hiring, leadership and other business signals into one connected view of each company, ranks opportunities against your ideal customer profile, and delivers the evidence and verified contacts to act on. Now it answers in Claude too: ask for today’s leads, then write the note in the same window.
Trusted by
Ligand Pharmaceuticals Incorporated
The company completed buying or selling a business or major assets. An 8-K is the notice a US public company must file within four business days of a major event.
www.ligand.comAI Executive Summary
AI-powered analysis of 8-K filing content
Ligand Pharmaceuticals acquired royalty and milestone payment rights for Santen Pharmaceutical's Ryjunea from Sydnexis for $23 million upfront, strategically expanding its pharmaceutical royalty portfolio and positioning for future milestone-based revenue.
Key Takeaways
Ligand paid $23 million upfront to acquire royalty and milestone payment rights to Ryjunea, a Santen Pharmaceutical product
This acquisition enhances Ligand's portfolio in pharmaceutical royalties, creating potential for significant future revenue from milestone payments
1 more takeaway
Filing Overview
What This Means
Ligand Pharmaceuticals Incorporated filed with the SEC. Fundz turns 8-K material events into an alert with the right executive attached.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
4 screens from a live account. No signup.